What is the success rate of Breyanzi?

Q: What is the success rate of Breyanzi?

Everyone will respond differently to Breyanzi (lisocabtagene maraleucel), and the success rate for someone else may be different than for you. Based on clinical trial data, the complete response rate in patients taking Breyanzi is around 20% to 73%, depending on the condition being treated.

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 31, 2025.

Official Answer by Drugs.com

The success rate of Breyanzi (lisocabtagene maraleucel) varies depending on the condition being treated. Clinical trial data show that complete response rates range from 20% to 73% across different types of lymphoma and leukemia.

Below are clinical trial results for Breyanzi in various conditions, with some patients experiencing partial response to treatment.

Large B-cell lymphoma

Breyanzi was studied in over 250 adults with refractory or relapsed B-cell lymphoma in a multicenter clinical trial. The study showed:

After treatment with Breyanzi, the complete remission rate was 54%.
Criteria: 2014 Lugano classification

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

The complete response rate among patients who took Breyanzi for relapsed or refractory CLL or SLL in a clinical trial called TRANSCEND-CLL was 20%. A total of 65 patients were treated with Breyanzi in the study.

Criteria: 2018 International Workshop CLL (iwCLL) criteria

Follicular lymphoma

In the TRANSCEND-FL clinical trial, adults with relapsed or refractory follicular lymphoma who took Breyanzi had a complete response rate of 73.4%. A total of 94 patients that were treated with Breyanzi were included in the final results. In order to be considered to have complete response, patients who did not have a negative bone marrow biopsy between their most recent disease progression and before starting lymphodepleting chemotherapy were required to have a negative bone marrow biopsy.

Mantle cell lymphoma

Out of 68 patients with relapsed or refractory mantle cell lymphoma who were treated with Breyanzi in the TRANSCEND-MCL trial, 67.6% saw a complete response.

Criteria: 2014 Lugano classification

Individual responses to Breyanzi vary, and partial responses were also observed in these trials. Speak with your healthcare provider to understand how these results may apply to your specific situation.

References

Breyanzi [package insert]. Updated May 2024. Juno Therapeutics, Inc. Accessed August 6, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed

U.S. Food and Drug Administration. 2021. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. Accessed August 6, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma

U.S. Food and Drug Administration. 2024. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma

U.S. Food and Drug Administration. 2024. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma

Does Truxima make you gain weight?

Weight gain has been reported in 11% of patients being treated with Truxima (rituximab) for non-Hodgkin’s lymphoma (NHL). Be sure to contact your doctor right away if you have a rapid or unexplained weight gain or fluid retention (edema), nausea, vomiting, diarrhea, or lack of energy when using Truxima, as you may need immediate medical care. Continue reading

What is the cost of Kymriah?

Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $633,000 for one treatment, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare.

What is the cost of Yescarta?

The cost of Yescarta is about $424,000 per treatment regimen, but most people do not pay this amount. Your insurance or the manufacturer may cover many of the costs for this treatment. Each dose of Yescarta is a customized treatment created using a patient’s own immune system to help fight lymphoma (a type of blood cancer).

What is the success rate of Breyanzi?

Large B-cell lymphoma

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Related questions

Follicular lymphoma

Mantle cell lymphoma

Read next

Does Truxima make you gain weight?

What is the cost of Kymriah?

What is the cost of Yescarta?

See also:

Aimovig

Botox

Imbruvica

Nurtec ODT

Depakote

Topamax

Emgality

Timolol

Valproic acid

Divalproex sodium

Related medical questions

Drug information

Related support groups